19,118 results match your criteria Oncology[Journal]


MEK and PD-L1 inhibition in colorectal cancer: a burning blaze turning into a flash in the pan.

Lancet Oncol 2019 Apr 16. Epub 2019 Apr 16.

Gastrointestinal Unit, Department of Medical Oncology, Institut Jules Bordet, Brussels 1000, Belgium; Université Libre de Bruxelles, Brussels, Belgium. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14702045193007
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(19)30076-2DOI Listing
April 2019
1 Read

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.

Lancet Oncol 2019 Apr 16. Epub 2019 Apr 16.

Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy. Electronic address:

Background: Microsatellite-stable metastatic colorectal cancer is typically unresponsive to immunotherapy. This phase 3 study was designed to assess atezolizumab plus cobimetinib in metastatic colorectal cancer. Here, we report the comparison of atezolizumab plus cobimetinib or atezolizumab monotherapy versus regorafenib in the third-line setting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30027-0DOI Listing

Intrahepatic Oxaliplatin and Systemic 5-FU +/- Cetuximab in Chemo-Naïve Patients with Liver Metastases from Colorectal Cancer.

Oncology 2019 Apr 18. Epub 2019 Apr 18.

Department of Oncology, Copenhagen University Hospital, Herlev and Gentofte, Herlev, Denmark.

Background: In case of response to chemotherapy, unresectable liver metastases from colorectal cancer can be converted to resectable and thereby obtain a chance of cure. The primary aim of this trial was to evaluate the response rate with intrahepatic oxaliplatin in combination with systemic 5-FU +/- cetuximab. Secondary aims were to evaluate the conversion rate from unresectable to resectable liver metastases, median progression-free survival, median overall survival, and toxicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000499314DOI Listing
April 2019
1 Read

Supporting Data vs Patient Requests in Oncology: When the Two Don't Coincide.

Oncology (Williston Park) 2019 04;33(4):156-8

Relationships between cancer patients and their oncologists flourish in a milieu of trust and goodwill. However, at times cancer patients may express strong preferences for medical tests, treatments, or other interventions that are not beneficial. Actively challenging these requests can be difficult and may threaten the patient-physician relationship. Read More

View Article

Download full-text PDF

Source
April 2019
1 Read

What to Do When Anti-PD-1 Therapy Fails in Patients With Melanoma.

Oncology (Williston Park) 2019 04;33(4):141-8

Monotherapy with immune checkpoint inhibitors, specifically those targeting programmed death 1 (PD-1), has revolutionized the treatment of metastatic melanoma: approximately 40% of patients achieve a partial or complete response, many of which are durable. However, a subset of patients who initially respond to therapy will progress, leaving the majority of patients in need of an effective second-line approach. While some standard therapies exist, there has been robust interest in utilizing targeted immunotherapy combinations in this population to overcome primary or acquired resistance. Read More

View Article

Download full-text PDF

Source
April 2019
2 Reads

Combining Chemotherapy and Immunotherapy for the Treatment of Triple-Negative Breast Cancer.

Authors:
Heather McArthur

Oncology (Williston Park) 2019 04;33(4):137-40

View Article

Download full-text PDF

Source

Recent Clinical Trials Explore Immunotherapies for Urothelial Carcinoma.

Authors:
Arjun V Balar

Oncology (Williston Park) 2019 04;33(4):132-6

View Article

Download full-text PDF

Source
April 2019
1 Read

Novel Targets and Precision Medicine for Prostate Cancer-Part 2: Tumor Profiling and Personalized Therapy in Patients With Castration-Resistant Prostate Cancer.

Oncology (Williston Park) 2019 04;33(4):128-31

Despite advances in the treatment of castration-resistant prostate cancer (CRPC), options remain limited and non-curative; thus, prostate cancer remains one of the deadliest cancers in men. The discovery of novel therapeutic targets is needed to improve outcomes for men with metastatic CRPC. Precision/personalized medicine creates new opportunities to discover these targets. Read More

View Article

Download full-text PDF

Source

Regorafenib for Metastatic Colorectal Cancer: Common Toxicities and Prevention Strategies.

Authors:
Amber Draper

Oncology (Williston Park) 2019 04;33(4):126-7

View Article

Download full-text PDF

Source
April 2019
1 Read

Importance of early treatment in metastatic prostate cancer: a question of life or death.

Authors:
Fred Saad

Lancet Oncol 2019 Apr 12. Epub 2019 Apr 12.

Department of Urology, Centre Hospitalier de l'Université de Montréal, Montreal, QC H2X 0A9, Canada. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14702045193015
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(19)30155-XDOI Listing
April 2019
1 Read

Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.

Lancet Oncol 2019 Apr 12. Epub 2019 Apr 12.

BC Cancer Agency-Vancouver Centre, Vancouver, BC, Canada.

Background: In the interim analyses of the LATITUDE study, the addition of abiraterone acetate plus prednisone to androgen deprivation therapy (ADT) led to a significant improvement in overall survival and radiographic progression-free survival compared with placebos plus ADT in men with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (mCSPC). Here, we present long-term survival outcomes and safety of abiraterone acetate plus prednisone and ADT from the final analysis of the LATITUDE study.

Methods: This is a multicentre, randomised, double-blind, phase 3 trial done at 235 sites in 34 countries. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30082-8DOI Listing
April 2019
1 Read

Therapeutic HPV vaccine for cervical intraepithelial neoplasia.

Authors:
Talha Khan Burki

Lancet Oncol 2019 Apr 12. Epub 2019 Apr 12.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30224-4DOI Listing

Myoepithelial Cell Carcinoma of the Oral Tongue: Case Report and Review of the Literature.

Clin Med Insights Oncol 2019 2;13:1179554919838254. Epub 2019 Apr 2.

Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, University of New Mexico Hospital, UNM School of Medicine, Albuquerque, NM, USA.

Background: Myoepithelial cell carcinoma is a rare malignant neoplasm of salivary gland origin that typically presents in the parotid gland and minor salivary glands. It has been described previously in head and neck sites such as buccal mucosa, alveolar ridge, and base of tongue.

Methods: A 55-year-old man presented with 30 years of right-sided tongue pain and 10 years of gradually worsening ulceration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179554919838254DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448097PMC
April 2019
2 Reads

NICE guidance on daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma.

Lancet Oncol 2019 Apr 10. Epub 2019 Apr 10.

Addenbrooke's Hospital, Cambridge, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30222-0DOI Listing

Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial.

Lancet Oncol 2019 Apr 8. Epub 2019 Apr 8.

Primary Children's Hospital, Salt Lake City, UT, USA.

Background: Hepatoblastoma treatment with curative intent requires surgical resection, but only about a third of newly diagnosed patients with hepatoblastoma have resectable disease at diagnosis. Patients who have upfront resection typically receive a total of 4-6 cycles of adjuvant chemotherapy post-surgery, with the combination of cisplatin, fluorouracil, and vincristine. We aimed to investigate whether event-free survival in children with hepatoblastoma who had complete resection at diagnosis could be maintained with two cycles of adjuvant chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30895-7DOI Listing
April 2019
1 Read

Bevacizumab in EGFR-positive NSCLC: time to change first-line treatment?

Lancet Oncol 2019 Apr 8. Epub 2019 Apr 8.

Department of Oncology, National Taiwan University Hospital and Graduate Institute of Oncology, National Taiwan University, Taipei 100, Taiwan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30085-3DOI Listing

Is it worth completely resecting hepatoblastoma at diagnosis?

Authors:
Piotr Czauderna

Lancet Oncol 2019 Apr 8. Epub 2019 Apr 8.

Department of Surgery and Urology for Children and Adolescents, Medical University of Gdansk, 80-210 Gdansk, Poland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30096-8DOI Listing

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.

Lancet Oncol 2019 Apr 8. Epub 2019 Apr 8.

Iwate Medical University School of Medicine, Morioka, Japan. Electronic address:

Background: Resistance to first-generation or second-generation EGFR tyrosine kinase inhibitor (TKI) monotherapy develops in almost half of patients with EGFR-positive non-small-cell lung cancer (NSCLC) after 1 year of treatment. The JO25567 phase 2 trial comparing erlotinib plus bevacizumab combination therapy with erlotinib monotherapy established the activity and manageable toxicity of erlotinib plus bevacizumab in patients with NSCLC. We did a phase 3 trial to validate the results of the JO25567 study and report here the results from the preplanned interim analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30035-XDOI Listing
April 2019
2 Reads

Treatment of Radiation-Induced Cognitive Decline in Adult Brain Tumor Patients.

Curr Treat Options Oncol 2019 Apr 8;20(5):42. Epub 2019 Apr 8.

Oncology, Medical Neuro-Oncology and Neuro-Oncology Research Program, Wake Forest Baptist Comprehensive Cancer Center, Medical Center Boulevard, Winston-Salem, NC, 27157-1082, USA.

Opinion Statement: Patients with either primary or metastatic brain tumors quite often have cognitive impairment. Maintaining cognitive function is important to brain tumor patients and a decline in cognitive function is generally accompanied by a decline in functional independence and performance status. Cognitive decline can be a result of tumor progression, depression/anxiety, fatigue/sleep dysfunction, or the treatments they have received. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0641-6DOI Listing

AACR Annual Meeting 2019.

Lancet Oncol 2019 Apr 4. Epub 2019 Apr 4.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30221-9DOI Listing
April 2019
2 Reads

Fulvestrant plus anastrozole for metastatic breast cancer.

Authors:
Talha Khan Burki

Lancet Oncol 2019 Apr 4. Epub 2019 Apr 4.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30217-7DOI Listing
April 2019
2 Reads

High-intensity end-of-life cancer care for young patients.

Authors:
Manjulika Das

Lancet Oncol 2019 Apr 4. Epub 2019 Apr 4.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30219-0DOI Listing
April 2019
2 Reads

Inotuzumab ozogamicin in acute lymphoblastic leukaemia.

Authors:
Elizabeth Gourd

Lancet Oncol 2019 Apr 4. Epub 2019 Apr 4.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30218-9DOI Listing
April 2019
8 Reads

Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study.

Lancet Oncol 2019 Apr 2. Epub 2019 Apr 2.

Medical Image Computing, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Background: The Response Assessment in Neuro-Oncology (RANO) criteria and requirements for a uniform protocol have been introduced to standardise assessment of MRI scans in both clinical trials and clinical practice. However, these criteria mainly rely on manual two-dimensional measurements of contrast-enhancing (CE) target lesions and thus restrict both reliability and accurate assessment of tumour burden and treatment response. We aimed to develop a framework relying on artificial neural networks (ANNs) for fully automated quantitative analysis of MRI in neuro-oncology to overcome the inherent limitations of manual assessment of tumour burden. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30098-1DOI Listing
April 2019
2 Reads

Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.

Lancet Oncol 2019 Apr 1. Epub 2019 Apr 1.

Cancer Research UK Centre, University of Southampton, Southampton, UK. Electronic address:

Background: Biologically distinct subtypes of diffuse large B-cell lymphoma can be identified using gene-expression analysis to determine their cell of origin, corresponding to germinal centre or activated B cell. We aimed to investigate whether adding bortezomib to standard therapy could improve outcomes in patients with these subtypes.

Methods: In a randomised evaluation of molecular guided therapy for diffuse large B-cell lymphoma with bortezomib (REMoDL-B), an open-label, adaptive, randomised controlled, phase 3 superiority trial, participants were recruited from 107 cancer centres in the UK (n=94) and Switzerland (n=13). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30935-5DOI Listing
April 2019
7 Reads

Improving R-CHOP in diffuse large B-cell lymphoma is still a challenge.

Authors:
Fabrice Jardin

Lancet Oncol 2019 Apr 1. Epub 2019 Apr 1.

Department of Clinical Hematology, Centre Henri Becquerel, INSERM U1245, Rouen University, Rouen 76038, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30021-XDOI Listing
April 2019
5 Reads

Fighting against the challenge of treating patients with late-line ovarian cancer: are we there yet?

Lancet Oncol 2019 Apr 1. Epub 2019 Apr 1.

Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome 00168, Italy; Catholic University of the Sacred Heart, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30087-7DOI Listing
April 2019
4 Reads

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.

Lancet Oncol 2019 Apr 1. Epub 2019 Apr 1.

Division of Gynecologic Oncology, Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine at St Joseph's Hospital, Phoenix, AZ, USA.

Background: Late-line treatment options for patients with ovarian cancer are few, with the proportion of patients achieving an overall response typically less than 10%, and median overall survival after third-line therapy of 5-9 months. In this study (QUADRA), we investigated the activity of niraparib monotherapy as the fourth or later line of therapy.

Methods: QUADRA was a multicentre, open-label, single-arm, phase 2 study that evaluated the safety and activity of niraparib in adult patients (≥18 years) with relapsed, high-grade serous (grade 2 or 3) epithelial ovarian, fallopian tube, or primary peritoneal cancer who had been treated with three or more previous chemotherapy regimens. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30029-4DOI Listing
April 2019
4 Reads

Treatment-Induced Cardiotoxicity in Breast Cancer: A Review of the Interest of Practicing a Physical Activity.

Oncology 2019 Apr 3;96(5):1-12. Epub 2019 Apr 3.

U1240 Imagerie Moléculaire et Stratégies Théranostiques, Institut National de la Santé et de la Recherche Médicale, Centre Jean PERRIN, Université Clermont Auvergne, Clermont-Ferrand, France.

Physical activity is known to prevent the occurrence of cancer and decrease the risk of breast cancer. At diagnosis of breast cancer, fewer than half of the patients reach the international recommendation for physical activity. However, breast cancer patients, and particularly HER2+ breast cancer patients, are exposed to treatment-induced cardiotoxicity because of a side effect of 2 molecules used in standard therapy to treat these tumors, i. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/499383
Publisher Site
http://dx.doi.org/10.1159/000499383DOI Listing
April 2019
4 Reads

Malignant priapism and germ cell tumour.

Lancet Oncol 2019 Apr;20(4):e224

Clinical Oncology Centre, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30075-0DOI Listing
April 2019
4 Reads

Smokeless tobacco control in 180 countries across the globe: call to action for full implementation of WHO FCTC measures.

Lancet Oncol 2019 Apr;20(4):e208-e217

Healis-Sekhsaria Institute for Public Health, Navi Mumbai, Maharashtra, India.

Smokeless tobacco is consumed by 356 million people globally and is a leading cause of head and neck cancers. However, global efforts to control smokeless tobacco use trail behind the progress made in curbing cigarette consumption. In this Policy Review, we describe the extent of the policy implementation gap in smokeless tobacco control, discuss key reasons on why it exists, and make recommendations on how to bridge this gap. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30084-1DOI Listing
April 2019
3 Reads
24.690 Impact Factor

Dose recommendations for anticancer drugs in patients with renal or hepatic impairment.

Lancet Oncol 2019 Apr;20(4):e200-e207

Department of Clinical Pharmacy, Radboud University Medical Center, Nijmegen, Netherlands. Electronic address:

Renal or hepatic impairment is a common comorbidity for patients with cancer either because of the disease itself, toxicity of previous anticancer treatments, or because of other factors affecting organ function, such as increased age. Because renal and hepatic function are among the main determinants of drug exposure, the pharmacokinetic profile might be altered for patients with cancer who have renal or hepatic impairment, necessitating dose adjustments. Most anticancer drugs are dosed near their maximum tolerated dose and are characterised by a narrow therapeutic index. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30145-7DOI Listing
April 2019
1 Read

ESMO-MCBS: setting the record straight - Authors' reply.

Lancet Oncol 2019 Apr;20(4):e193

Department of Clinical Oncology, Guy's & St Thomas' NHS Trust, London, UK; Institute of Cancer Policy, King's College London, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30166-4DOI Listing
April 2019
4 Reads

ESMO-MCBS: setting the record straight.

Lancet Oncol 2019 Apr;20(4):e192

European Society for Medical Oncology-Magnitude of Clinical Benefit Scale Working Group, Lugano, Switzerland; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30174-3DOI Listing
April 2019
1 Read

PET-guided, BEACOPP therapy in advanced Hodgkin lymphoma.

Lancet Oncol 2019 Apr;20(4):e189

Department of Nuclear Medicine, Centre Hospitalier Universitaire, F-33000 Bordeaux, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30162-7DOI Listing
April 2019
6 Reads

PET-guided, BEACOPP therapy in advanced Hodgkin lymphoma.

Lancet Oncol 2019 Apr;20(4):e188

Department of Pharmacy Services and Clinical Pharmacy, Michigan Medicine, Ann Arbor, MI 48109, USA; University of Michigan College of Pharmacy, MI, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30081-6DOI Listing
April 2019
5 Reads

Interactive architecture-UV protection unfolding above you!

Lancet Oncol 2019 Apr;20(4):479-480

Prof George Thomas Kapelos, Ryerson University, Toronto, ON, Canada. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14702045193014
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(19)30141-XDOI Listing
April 2019
3 Reads

Use of medical cannabis: perceptions of Israeli oncologists.

Lancet Oncol 2019 Apr;20(4):475-477

Institute of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14702045193007
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(19)30077-4DOI Listing
April 2019
8 Reads

Advocacy for a New Oncology Research Paradigm: The Model of Bevacizumab in Triple-Negative Breast Cancer in a French Cohort Study.

Oncology 2019 Apr 2:1-6. Epub 2019 Apr 2.

Department of Pharmacology, Lucien Neuwirth Cancer Institute, Saint-Priest-en-Jarez, France.

Background: Triple-negative breast cancer remains a disease with poor prognosis and few treatment options, due to the lack of therapeutic targets. Bevacizumab, the first anti-VEGF agent approved in the treatment of cancer, has demonstrated efficacy in breast cancer in combination with paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer. Despite the fact that the benefit was particularly significant for triple-negative breast cancer with its approval in 2008 by the FDA, this decision was later reversed as there was no improvement in overall survival in addition to significant costs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000499583DOI Listing
April 2019
1 Read

The Changing Landscape of Management of Metastatic Renal Cell Carcinoma: Current Treatment Options and Future Directions.

Curr Treat Options Oncol 2019 Apr 1;20(5):41. Epub 2019 Apr 1.

Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, Duarte, CA, 91010, USA.

Opinion Statement: For the practicing clinician, the dilemma becomes how most appropriate to sequence the aforementioned regimens. It is challenging to be dogmatic, as there are no comparative studies juxtaposing novel front-line options directly-all of the available studies utilize a comparator arm of sunitinib. With this in mind, the selection of front-line therapy with a patient with mRCC should involve a thorough discussion of both efficacy and safety of available options. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0638-1DOI Listing
April 2019
1 Read

Optimal Management of Upper Tract Urothelial Carcinoma: an Unmet Need.

Curr Treat Options Oncol 2019 Apr 1;20(5):40. Epub 2019 Apr 1.

Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.

Opinion Statement: Upper tract urothelial carcinoma (UTUC) is a rare genitourinary entity of the renal pelvis and the ureter characterized by a more aggressive disease phenotype when compared with urothelial carcinoma of the bladder (UCB) with more than half of UTUC cases presenting with invasive disease at diagnosis compared to 20% for bladder tumors. There is growing evidence suggesting that its distinct natural history from that of bladder cancer can be related to several genetic and epigenetic differences. Treatment of low-risk disease consists of kidney-sparing surgeries such as ureteroscopic and percutaneous treatments, segmental ureterectomy, and adjuvant topical and intracavitary chemo-immunotherapies. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-019-0637-2
Publisher Site
http://dx.doi.org/10.1007/s11864-019-0637-2DOI Listing
April 2019
3 Reads